Cerevel Therapeutics Holdings Inc. (NASDAQ: CERE) is -6.57% lower on its value in year-to-date trading and has touched a low of $9.00 and a high of $18.83 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CERE stock was last observed hovering at around $15.26 in the last trading session, with the day’s gains setting it 0.23% off its average median price target of $22.00 for the next 12 months. It is also 32.65% off the consensus price target high of $23.00 offered by 3 analysts, but current levels are 26.24% higher than the price target low of $21.00 for the same period.
Currently trading at $15.49, the stock is 8.93% and 5.58% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.25 million and changing 1.51% at the moment leaves the stock 18.03% off its SMA200. CERE registered a gain of 54.75% in past 6-months. The firm has a 50-day simple moving average (SMA 50) of $14.80 and a 200-day simple moving average (SMA200) of $13.57.
The stock witnessed a 24.42% loss in the last 1 month and extending the period to 3 months gives it a 23.72%, and is 9.62% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.51% over the week and 7.45% over the month.
Distance from 52-week low is 72.11% and -17.76% from its 52-week high.
Cerevel Therapeutics Holdings Inc. (CERE) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Cerevel Therapeutics Holdings Inc. (CERE) is a “Buy”. 3 analysts offering their recommendations for the stock have an average rating of 1.30, where 0 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Cerevel Therapeutics Holdings Inc. is expected to release its quarterly report on 09/01/2021 and quarterly earnings per share for the current quarter are estimated at -$0.41.The EPS is expected to grow by 14.90% this year.
Cerevel Therapeutics Holdings Inc. (CERE) Top Institutional Holders
67 institutions hold shares in Cerevel Therapeutics Holdings Inc. (CERE), with 27.47M shares held by insiders accounting for 21.58% while institutional investors hold 98.54% of the company’s shares. The shares outstanding are 78.58M, and float is at 39.16M with Short Float at 9.24%. Institutions hold 77.27% of the Float.
The top institutional shareholder in the company is Bain Capital Investors, LLC with over 60.63 million shares valued at $1.01 billion. The investor’s holdings represent 47.64% of the CERE Shares outstanding. As of Dec 30, 2020, the second largest holder is Perceptive Advisors Llc with 4.54 million shares valued at $75.34 million to account for 3.57% of the shares outstanding. The other top investors are FMR, LLC which holds 4.31 million shares representing 3.39% and valued at over $71.52 million, while Price (T.Rowe) Associates Inc holds 2.67% of the shares totaling 3.39 million with a market value of $56.24 million.
Cerevel Therapeutics Holdings Inc. (CERE) Insider Activity
A total of 5 insider transactions have happened at Cerevel Therapeutics Holdings Inc. (CERE) in the last six months, with sales accounting for 0 and purchases happening 5 times. The most recent transaction is an insider purchase by BAIN CAPITAL INVESTORS LLC, the company’s 10% Owner. SEC filings show that BAIN CAPITAL INVESTORS LLC bought 332,293 shares of the company’s common stock on Nov 09 at a price of $10.30 per share for a total of $3.42 million. Following the purchase, the insider now owns 60.63 million shares.
Cerevel Therapeutics Holdings Inc. disclosed in a document filed with the SEC on Nov 09 that Koppel Adam (Director) bought a total of 332,293 shares of the company’s common stock. The trade occurred on Nov 09 and was made at $10.30 per share for $3.42 million. Following the transaction, the insider now directly holds 60.63 million shares of the CERE stock.
Still, SEC filings show that on Nov 09, Gordon Christopher R (Director) acquired 332,293 shares at an average price of $10.30 for $3.42 million. The insider now directly holds 60,632,356 shares of Cerevel Therapeutics Holdings Inc. (CERE).